BioSpace News Archive

Regulatory News: MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer reported its cash position as of March 31, 2022, and its revenues for the first quarter of 2022.

Subsequent to study results previously released by Spinal Resources Inc, the U.S. Patent and Trademark Office has issued the Variable-Dimension/Variable-Stiffness Spinal Fixation Rod with Bezier Surface Geometry a patent.

RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a commercial update on Thursday, May 12, 2022, before U.S. financial markets open.

Coherus BioSciences, Inc. today announced the appointment of former investment banker and renowned biotech strategist Charlie Newton to its Board of Directors.

Avance Biosciences announced completion of move-in and validation of an additional 26,000 square feet of laboratory space acquired in the past year.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment, is advancing efforts to establish measurable residual disease as a surrogate endpoint for overall survival in the treatment of acute myeloid leukemia.

VistaGen Therapeutics, Inc. (Nasdaq: VTGN),) announced today a key regulatory update on its PALISADE Phase 3 Program for PH94B for the acute treatment of anxiety in adults with social anxiety disorder (SAD).

Enlivex Therapeutics Ltd. today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater China and South Korea.